November 22, 2022 -- PerkinElmer has announced the launch of its "ready-to-use" adeno-associated virus vectors (AAV) detection kits to support researchers working on gene therapies for a variety of diseases.
The high-throughput viral assays are designed to help researchers quickly and easily characterize viral vector particles being produced to enable decision-making for safe and efficient gene transfer, according to the company.
The validated, fully automatable, and no-wash assays are built on PerkinElmer's AlphaLISA technology which requires no separation. The kits provide researchers with expanded options to measure viral titers beyond enzyme-linked immunosorbent assay (ELISA) and other wash-based systems, which can be time-consuming and limited in assay range.
In addition, each of the seven kits detects specific serotypes to target different cell types in the body for gene therapy application, according to PerkinElmer.
The goal of the kits is to streamline gene therapy research and development workflows by "eliminating long, tedious protocols while expanding the detection range to enable potential cures for people living with cancer, Alzheimer's, muscular dystrophy, infectious diseases, and more," Dr. Alan Fletcher, senior vice president of Life Sciences at PerkinElmer, said in a statement.